about
A soluble form of LMIR5/CD300b amplifies lipopolysaccharide-induced lethal inflammation in sepsisMyelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutationsTwo types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling.The molecular basis of myeloid malignancies.NK cells activated by Interleukin-4 in cooperation with Interleukin-15 exhibit distinctive characteristics.Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD).Characterization of leukocyte mono-immunoglobulin-like receptor 7 (LMIR7)/CLM-3 as an activating receptor: its similarities to and differences from LMIR4/CLM-5.Identification of the novel 3' UTR sequences of human IL-21 mRNA as potential targets of miRNAs.Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition.Mature resting Ly6C(high) natural killer cells can be reactivated by IL-15.Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis.MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-C(m))-induced myeloid leukemia.Eμ/miR-125b transgenic mice develop lethal B-cell malignancies.An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells.Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion.Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.Neutrophils alleviate fibrosis in the CCl4-induced mouse chronic liver injury model.
P50
Q28588017-5FA5520B-2B27-46E5-8D11-B4D863ABAFA9Q28590040-FEBE7C90-E675-4678-8216-52C2CE03EEDAQ33706874-BB058978-A707-4D32-A477-9D72C4C63111Q34625798-4B99E935-0D86-4682-B2D3-9F6F228211C9Q35103708-66BA8E1E-E4D1-42A9-8D91-2C73E8B5F812Q37247511-0D988455-BCCD-42A4-BBED-0BEC8EB843C5Q38641382-BCF61F19-BBCC-4537-B3E9-2E23142323D6Q39659418-6B74056A-5F02-4F42-902E-318D513341D7Q40086494-6C431B48-C4AD-4F7E-A4C8-A9034CB38A0DQ41116097-E3159C0A-1595-4BC1-92CD-2ECBAA47828EQ42208071-4FAB81E2-7F03-4450-BF49-539EC9A84F50Q42805287-ECC3EBCB-9338-4E53-ACCD-B96634F5C589Q44210348-B11A7D01-F082-4748-B711-7EF7AC78A6C6Q45853633-E3CAA634-A173-45BF-969A-F8C927B8C520Q45949387-9408DBFE-268F-4657-939E-88D5D313051FQ47409251-ABD2D955-B0DB-4743-B193-1B5941054073Q54352847-605111A0-8EBB-43F0-8FCC-6F52DF77749CQ55260347-643A8877-9E82-4178-84C4-2E9A96A256D2
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Yutaka Enomoto
@ast
Yutaka Enomoto
@en
Yutaka Enomoto
@es
Yutaka Enomoto
@nl
type
label
Yutaka Enomoto
@ast
Yutaka Enomoto
@en
Yutaka Enomoto
@es
Yutaka Enomoto
@nl
prefLabel
Yutaka Enomoto
@ast
Yutaka Enomoto
@en
Yutaka Enomoto
@es
Yutaka Enomoto
@nl
P31
P496
0000-0002-6346-9362